T lymphocyte heterogeneity in NSCLC: implications for biomarker development and therapeutic innovation

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) treatment, but patient responses vary.
• Tumor-immune interactions significantly influence treatment outcomes, necessitating a deeper understanding of the tumor microenvironment.

Purpose of the Study:

• To review current knowledge on tumor-infiltrating lymphocyte (TIL) biology in NSCLC.
• To highlight novel biomarkers and strategies for predicting and enhancing ICI efficacy.
• To propose integrated frameworks for optimizing NSCLC immunotherapy.

Main Methods:

• Literature review of recent studies on TILs, biomarkers, and immunogenic remodeling.
• Analysis of emerging biomarkers including TCR clonality, spatial TIL distribution, and exhaustion markers (PD-1, TCF1, TIM-3).
• Integration of single-cell omics and AI-driven spatial analysis.

Main Results:

• CD8+ cytotoxic T cells and regulatory T cells (Tregs) are key regulators of immune responses in NSCLC.
• Biomarkers beyond PD-L1, such as TCR clonality and exhaustion markers, show promise in predicting ICI response.
• Radiotherapy can induce immunogenic remodeling, and peripheral T cell dynamics offer insights into immune monitoring.

Conclusions:

• Multidimensional frameworks integrating TIL biology and advanced analytical methods can overcome immunotherapy resistance in NSCLC.
• Precision modulation of the tumor immune microenvironment is crucial for advancing NSCLC immunotherapy.
• Further research into TILs and novel biomarkers will refine treatment strategies and improve patient outcomes.